Opiate Dependence disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OPT003 MIFTS: 55	Opiate Dependence Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence ¹² ¹⁵

Opioid Dependence ⁷⁶ ⁵⁵

Opioid-Related Disorders ⁷³

Opioid Type Dependence ¹²

Opiate Addiction ⁷³

Classifications:

MalaCards categories:
Anatomical: Mental diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Mental and behavioural disorders

Mental and behavioural disorders due to psychoactive substance use

Mental and behavioural disorders due to use of opioids

Mental and behavioural disorders due to use of opioids: Dependence syndrome

External Ids:

Disease Ontology ¹² DOID:2559

ICD10 ³³ F11.2

ICD9CM ³⁵ 304.0 304.00

MeSH ⁴⁴ D009293

SNOMED-CT ⁶⁸ 75544000

UMLS ⁷³ C0524662 C0027412

Sources

Summaries for Opiate Dependence

Disease Ontology : ¹² A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid dependence, is related to opioid dependence 1 and opioid addiction. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Buprenorphine and Naloxone have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : ⁷⁶ Opioid use disorder is a problematic pattern of opioid use that causes significant impairment or... more...

Sources

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)

#	Related Disease	Score	Top Affiliating Genes
1	opioid dependence 1	33.8	ODS1 OPRM1
2	opioid addiction	31.5	DRD2 OPRD1 OPRK1 OPRM1
3	morphine dependence	31.4	CREB1 OPRD1 OPRK1 OPRM1
4	heroin dependence	31.1	DRD2 OPRD1 OPRM1 PDYN
5	psychotic disorder	30.4	DRD2 DRD3 SLC6A4 TPH1
6	substance abuse	30.1	DRD2 DRD3 SLC6A4
7	personality disorder	30.0	DRD2 SLC6A4 TPH1
8	conduct disorder	30.0	DRD2 SLC6A4 TPH1
9	panic disorder	29.9	POMC SLC6A4 TPH1
10	withdrawal disorder	29.9	OPRM1 PDYN POMC
11	neonatal abstinence syndrome	29.8	OPRD1 OPRK1 OPRM1
12	alcohol abuse	29.8	DRD2 DRD3 SLC6A4
13	schizoaffective disorder	29.7	DRD2 DRD3 SLC6A4
14	schizophrenia	29.6	DRD2 DRD3 SLC6A4 TH TPH1
15	attention deficit-hyperactivity disorder	29.6	DRD2 DRD3 OPRM1 SLC6A4 TH TPH1
16	restless legs syndrome	29.5	DRD2 DRD3 POMC TH
17	pain agnosia	29.1	OPRK1 OPRM1 PDYN POMC
18	bipolar disorder	29.1	CREB1 DRD2 DRD3 IGF1 SLC6A4 TH
19	disease of mental health	29.0	DRD2 DRD3 OPRM1 PDYN POMC SLC6A4
20	alcohol dependence	28.6	DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
21	drug dependence	28.4	DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
22	gangliocytoma	10.2	POMC TH
23	acidophil adenoma	10.2	IGF1 POMC
24	pituitary infarct	10.2	IGF1 POMC
25	avoidant personality disorder	10.2	SLC6A4 TPH1
26	empty sella syndrome	10.2	IGF1 POMC
27	sick building syndrome	10.2	POMC VEGFA
28	sheehan syndrome	10.2	IGF1 POMC
29	cerebral hypoxia	10.2	CREB1 IGF1
30	alcohol-induced mental disorder	10.1	DRD2 SLC6A4
31	toxic encephalopathy	10.1	CREB1 NGF TH
32	polysubstance abuse	10.1	DRD2 DRD3
33	hyperpituitarism	10.1	IGF1 POMC
34	chronic fatigue syndrome	10.1	IGF1 POMC SLC6A4
35	mental depression	10.1	POMC SLC6A4 TPH1
36	galactorrhea	10.1	DRD2 IGF1
37	anorexia nervosa	10.1	IGF1 POMC SLC6A4
38	endocrine organ benign neoplasm	10.1	IGF1 NGF POMC
39	tardive dyskinesia	10.1	DRD2 DRD3
40	prolactin producing pituitary tumor	10.1	DRD2 NGF
41	pituitary tumors	10.1	IGF1 POMC VEGFA
42	impulse control disorder	10.1	DRD2 DRD3
43	alcoholic psychosis	10.1	DRD2 SLC6A4
44	central nervous system disease	10.1	NGF SLC6A4 TH
45	pathological gambling	10.1	DRD2 DRD3 SLC6A4
46	migraine without aura	10.1	DRD2 DRD3 SLC6A4
47	gonadal disease	10.1	IGF1 POMC VEGFA
48	delusional disorder	10.1	DRD2 DRD3 TH
49	west syndrome	10.1	POMC TH TPH1
50	nervous system disease	10.1	NGF TH VEGFA

Graphical network of the top 20 diseases related to Opiate Dependence:

Sources

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

⁴⁶ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.34	CREB1 DRD2 DRD3 NGF OPRD1 OPRK1
2	homeostasis/metabolism	MP:0005376	10.28	CREB1 DRD2 DRD3 IGF1 NGF OPRD1
3	growth/size/body region	MP:0005378	10.23	CREB1 DRD2 DRD3 IGF1 NGF OPRM1
4	cardiovascular system	MP:0005385	10.21	CREB1 DRD2 DRD3 IGF1 NGF POMC
5	integument	MP:0010771	10.18	DRD2 IGF1 NGF OPRD1 OPRK1 OPRM1
6	endocrine/exocrine gland	MP:0005379	10.13	CREB1 DRD2 IGF1 OPRK1 OPRM1 POMC
7	adipose tissue	MP:0005375	10.08	DRD2 DRD3 IGF1 OPRM1 PDYN POMC
8	mortality/aging	MP:0010768	10.07	CREB1 DRD2 DRD3 IGF1 NGF OPRM1
9	nervous system	MP:0003631	10.07	CREB1 DRD2 DRD3 IGF1 NGF OPRD1
10	digestive/alimentary	MP:0005381	9.97	DRD2 DRD3 OPRK1 OPRM1 PDYN VEGFA
11	muscle	MP:0005369	9.87	CREB1 DRD2 IGF1 NGF SLC6A4 TPH1
12	no phenotypic analysis	MP:0003012	9.76	DRD2 NGF OPRD1 OPRM1 PDYN POMC
13	normal	MP:0002873	9.56	CREB1 DRD2 IGF1 NGF OPRM1 SLC6A4
14	respiratory system	MP:0005388	9.1	CREB1 DRD2 IGF1 TH TPH1 VEGFA

Sources

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Buprenorphine

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

52485-79-7

40400 644073

Naloxone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

465-65-6

5284596

Naltrexone

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

16590-41-3

5360515

Methadone

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

76-99-3

4095

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

93-14-1

3516

Ethanol

Approved

Phase 4,Phase 2,Phase 3,Not Applicable

64-17-5

702

Dopamine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

51-61-6, 62-31-7

681

Bupivacaine

Approved, Investigational

Phase 4,Phase 2,Phase 3,Not Applicable

2180-92-9, 38396-39-3

2474

Ribavirin

Approved

Phase 4,Phase 3

36791-04-5

37542

Peginterferon alfa-2b

Approved

Phase 4

99210-65-8, 215647-85-1

Ketamine

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

6740-88-1

3821

Valproic Acid

Approved, Investigational

Phase 4,Not Applicable

99-66-1

3121

Nicotine

Approved

Phase 4,Phase 3,Phase 1,Not Applicable

54-11-5

942 89594

Norepinephrine

Approved

Phase 4,Phase 1,Phase 2

51-41-2

439260

Tramadol

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

27203-92-5

33741

Benzocaine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

94-09-7, 1994-09-7

2337

tannic acid

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

Oxycodone

Approved, Illicit, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

76-42-6

5284603

Morphine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

57-27-2

5288826

gamma-Aminobutyric acid

Approved, Investigational

Phase 4,Phase 2

56-12-2

119

Gabapentin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

60142-96-3

3446

Sofosbuvir

Approved

Phase 4

1190307-88-0

45375808

Rifapentine

Approved, Investigational

Phase 4

61379-65-5

6323497

Isoniazid

Approved, Investigational

Phase 4

54-85-3

3767

Codeine

Approved, Illicit

Phase 4

76-57-3

5284371

Acetaminophen

Approved

Phase 4,Not Applicable

103-90-2

1983

Emtricitabine

Approved, Investigational

Phase 4

143491-57-0

60877

Cobicistat

Approved

Phase 4

1004316-88-4

Oxymorphone

Approved, Investigational, Vet_approved

Phase 4

76-41-5

5284604

Heroin

Illicit, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

561-27-3

5462328

Tenofovir

Experimental, Investigational

Phase 4

147127-20-6

464205

Narcotic Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Narcotics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Analgesics, Opioid

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Opiate Alkaloids

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Buprenorphine, Naloxone Drug Combination

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Excitatory Amino Acid Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anesthetics, General

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anesthetics, Intravenous

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anesthetics

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Neurotransmitter Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Excitatory Amino Acids

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Chlorpheniramine, phenylpropanolamine drug combination

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antitussive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Respiratory System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Psychotropic Drugs

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 490)

#	Name	Status	NCT ID	Phase	Drugs
1	Buprenorphine and Integrated HIV Care Evaluation	Unknown status	NCT00124358	Phase 4	Buprenorphine
2	Integrating Buprenorphine Into HIV Treatment	Unknown status	NCT00241930	Phase 4
3	Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice	Completed	NCT00007527	Phase 4	naloxone;buprenorphine
4	Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence	Completed	NCT00555425	Phase 4
5	Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy	Completed	NCT01045278	Phase 4	Pegylated interferon-alfa-2b and ribavirin
6	Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence	Completed	NCT01903005	Phase 4	Higher bioavailability BNX sublingual tablets
7	Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan	Completed	NCT00901875	Phase 4	Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
8	Integrating Buprenorphine Into the SFGH AIDS Program	Completed	NCT00263458	Phase 4
9	Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14	Completed	NCT00015340	Phase 4	Buprenorphine/naloxone
10	Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population	Completed	NCT02038790	Phase 4	Suboxone Sublingual Film;Zubsolv sublingual tablets
11	A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration	Completed	NCT01453374	Phase 4	VIVITROL 380mg
12	Counseling for Primary Care Office-based Buprenorphine	Completed	NCT00595764	Phase 4
13	Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia	Completed	NCT00300794	Phase 4	Ketamine
14	Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients	Completed	NCT00879996	Phase 4	Methadone;Buprenorphine/naloxone
15	Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans	Completed	NCT01096550	Phase 4
16	A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)	Completed	NCT00605033	Phase 4	Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
17	Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment	Completed	NCT00844272	Phase 4
18	Treatment of Polydrug-Using Opiate Dependents During Withdrawal	Completed	NCT00367874	Phase 4	Buprenorphine;Valproate
19	HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)	Completed	NCT03583138	Phase 4	buprenorphine
20	Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients	Completed	NCT01559454	Phase 4	Methadone;Buprenorphine/naloxone
21	Relapse Prevention to Reduce HIV Among Women Prisoners	Completed	NCT00763958	Phase 4	Placebo;Buprenorphine
22	A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)	Completed	NCT00604188	Phase 4	Suboxone (SCH 000484);Subutex (SCH 028444)
23	Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)	Completed	NCT00684073	Phase 4	buprenorphine;buprenorphine/naloxone
24	Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)	Completed	NCT00798538	Phase 4
25	Pre-Release VIVITROL for Opioid Dependent Inmates	Completed	NCT01563718	Phase 4	naltrexone for extended release injectable suspension
26	An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence	Completed	NCT01047527	Phase 4	Transdermal nicotine patch
27	Desvenlafaxine in Opioid-Dependent Patients	Completed	NCT02200406	Phase 4	Desvenlafaxine
28	Neurocognitive Effects of Opiate Agonist Treatment	Completed	NCT01733693	Phase 4	Buprenorphine;Methadone
29	Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment	Completed	NCT02032433	Phase 4	Extended-Release Naltrexone;Buprenorphine-Naloxone
30	Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia	Completed	NCT02396979	Phase 4	Methadone
31	Naltrexone Treatment for Alcoholic Women	Completed	NCT00000448	Phase 4	naltrexone;Placebo
32	Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT	Completed	NCT01471145	Phase 4	Naltrexone
33	Buprenorphine and Integrated HIV Care	Completed	NCT00317460	Phase 4
34	Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery	Recruiting	NCT03647774	Phase 4	Extended release naltrexone
35	A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic	Recruiting	NCT03235154	Phase 4	sofosbuvir/velpatasvir
36	Houston Emergency Opioid Engagement System	Recruiting	NCT03396276	Phase 4	Suboxone
37	Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings	Recruiting	NCT03089983	Phase 4	Naltrexone;Methadone;Isoniazid;Rifapentine
38	Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures	Recruiting	NCT03305666	Phase 4	Liposomal bupivacaine injection;Bupivacaine indwelling catheter
39	A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse	Recruiting	NCT03033732	Phase 4	Methadone;Buprenorphine-Naloxone
40	Minimizing Narcotic Analgesics After Endocrine Surgery	Recruiting	NCT03469310	Phase 4	Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
41	Switch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on Methadone	Recruiting	NCT03549312	Phase 4	Genvoya;Epclusa
42	Biomarkers of Injectable Extended Release Naltrexone Treatment	Active, not recruiting	NCT02324725	Phase 4	Naltrexone
43	Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO)	Active, not recruiting	NCT01936857	Phase 4	Buprenorphine/naloxone;Methadone Maintenance Therapy
44	Extended Release Naltrexone for Opioid-Dependent Youth	Active, not recruiting	NCT01843023	Phase 4	Extended Release Naltrexone;Buprenorphine
45	Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain	Active, not recruiting	NCT02741076	Phase 4	Morphine Sulfate ER;Oxycodone ER;Oxymorphone ER
46	Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings	Enrolling by invitation	NCT02978417	Phase 4	Naltrexone for extended-release injectable suspension;Oral naltrexone
47	Liposomal Bupivacaine in Ambulatory Hand Surgery	Enrolling by invitation	NCT02933814	Phase 4	Liposomal Bupivicaine
48	XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept	Not yet recruiting	NCT03604159	Phase 4	Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
49	Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption	Not yet recruiting	NCT03534102	Phase 4	Improved Opioid-Tapering Instructions
50	Gabapentin Regimens and Their Effects on Opioid Consumption	Not yet recruiting	NCT03334903	Phase 4	Gabapentin

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

clonidine hcl pwdr

clonidine hydrochloride

levomethadyl

levomethadyl acetate hydrochloride

methadone

methadone hydrochloride

nalmefene

nalmefene hydrochloride

naloxone hydrochloride

naltrexone

naltrexone hydrochloride

Sources

Genetic Tests for Opiate Dependence

Sources

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

⁴¹

Testes, Brain, Liver, Bone, Eye, Fetal Brain, Pituitary

Sources

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 997)

#	Title	Authors	Year
1	Opiate Dependence or Addiction?: A Review of the Centers for Disease Control and Prevention Guidelines for Management of Chronic Pain. ( 29505462 )	Dobbs G.C....Fogger S.A.	2018
2	Predicting health-related quality of life (EQ-5D-5A L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP. ( 29843726 )	Peak J....Frew E.	2018
3	Factors predicting opioid dependence in patients undergoing surgery for degenerative spondylolisthesis: analysis from the MarketScan databases. ( 29914294 )		2018
4	The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. ( 30157924 )	Ahmadi J...Ehsaei Z	2018
5	Opioid Dependence and Health Care Utilization Following Decompression and Fusion in Patients with Adult Degenerative Scoliosis. ( 30015717 )	Sharma M...Boakye M	2018
6	Health care utilization and overall costs based on opioid dependence in patients undergoing surgery for degenerative spondylolisthesis. ( 29712535 )	Sharma M...Boakye M	2018
7	Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study. ( 29807218 )	Pikovsky M...Degenhardt L	2018
8	Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS. ( 30391868 )	West R...Guevara M	2018
9	Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. ( 29333880 )	Crist RC...Berrettini WH	2018
10	Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients. ( 29346444 )	Tran BX...Latkin CA	2018
11	Associations between pharmacotherapy for opioid dependence and clinical and criminal justice outcomes among adults with co-occurring serious mental illness. ( 29415846 )	Robertson AG...Swartz MS	2018
12	Genome-wide Association Study Identifies a Regulatory Variant of RGMA Associated With Opioid Dependence in European Americans. ( 29478698 )	Cheng Z...Gelernter J	2018
13	Opioid Omission Is Not Opioid Sparing. Response to "Surgery-Induced Opioid Dependence: Adding Fuel to the Fire?" ( 29481439 )	Moore DL	2018
14	Mindfulness-based interventions modulate structural network strength in patients with opioid dependence. ( 29494858 )	Fahmy R...Wolf RC	2018
15	Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence. ( 29560596 )	Saucier R...Dasgupta N	2018
16	Management of chronic pain and opioid dependence with buprenorphine/naloxone. ( 29573109 )	Chang HM...Chen LY	2018
17	Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. ( 29793599 )	Higgins C...Matthews K	2018
18	Opioid Dependence and Prolonged Length of Stay in Lumbar Fusion: A Retrospective Study Utilizing the National Inpatient Sample 2003-2014. ( 29794587 )	Tank A...Rubin DS	2018
19	Correction to: Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence. ( 29796833 )	Saucier R...Dasgupta N	2018
20	Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. ( 29806872 )	Solli KK...Kunoe N	2018
21	Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin. ( 29857327 )	Neale J...Strang J	2018
22	Serum BDNF levels in patients with opioid dependence during the early withdrawal period: A case control study. ( 29859931 )	Sarkar S...Kumar M	2018
23	Authors' Response to Silverman and Colleagues' Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence". ( 29956219 )	Dasgupta N...Wolfe D	2018
24	Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence". ( 29956220 )	Silverman B...Akerman S	2018
25	Non-medical Cannabis Self-Exposure as a Dimensional Predictor of Opioid Dependence Diagnosis: A Propensity Score Matched Analysis. ( 29997535 )	Butelman ER...Kreek MJ	2018
26	Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. ( 30107320 )	Larance B...Degenhardt L	2018
27	Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence. ( 30117074 )	Heo YA...Scott LJ	2018
28	Dynamic associations between opioid use and anhedonia: A longitudinal study in opioid dependence. ( 30130143 )	Lubman DI...Allen NB	2018
29	Supervised Injectable Opioid Treatment for the Management of Opioid Dependence. ( 30132259 )	Bell J...Lintzeris N	2018
30	Effect of opioid dependence or abuse on opioid utilization after shoulder arthroplasty. ( 30148070 )	Berglund DD...Levy JC	2018
31	Which Criteria to Use to Identify Metabolic Syndrome among Patients with Addictive Disorders?: Observations among Patients with Alcohol and Opioid Dependence Syndrome. ( 30148108 )	Singh Balhara YP...Gupta R	2018
32	Improving outcomes in the treatment of opioid dependence (IOTOD): reflections on the impact of a medical education initiative on healthcare professionals' attitudes and clinical practice. ( 30202635 )	Webster S...Marsden J	2018
33	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. ( 30280448 )	Nielsen S...Larance B	2018
34	Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence. ( 30300292 )	Knuijver T...Schellekens A	2018
35	Chronic co-administration of nalbuphine attenuates the development of opioid dependence. ( 30312633 )	Raghav R...Kumar P	2018
36	Substance misuse in patients who have comorbid chronic pain in a clinical population receiving methadone maintenance therapy for the treatment of opioid dependence. ( 30368067 )	Higgins C...Matthews K	2018
37	Can Tramadol be Used for Maintenance Treatment of Opioid Dependence? ( 30395757 )	Sarkar S...Singh Balhara YP	2018
38	A computational strategy for finding novel targets and therapeutic compounds for opioid dependence. ( 30403753 )	Wu X...Wu W	2018
39	ANCO-GeneDB: annotations and comprehensive analysis of candidate genes for alcohol, nicotine, cocaine and opioid dependence. ( 30403795 )	Hu R...Zhao Z	2018
40	Interrelationship of Opioid Dependence, Impaired Impulse Control, and Depressive Symptoms: An Open-Label Cross-Sectional Study of Patients in Maintenance Therapy. ( 30453290 )	Peters L...Soyka M	2018
41	Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial. ( 30460781 )	Wang X...Hao W	2018
42	Transcranial direct current stimulation to prevent and treat surgery-induced opioid dependence: a systematic review. ( 30516441 )	Gallucci A...Fregni F	2018
43	A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. ( 27958381 )	Crist RC...Berrettini WH	2018
44	Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. ( 28402682 )	Noller GE...Yazar-Klosinski B	2018
45	Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. ( 28576389 )	Soares WE...Friedmann PD	2018
46	Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence. ( 28593748 )	Oviedo-Joekes E...Schechter MT	2018
47	An analysis of genetic association in opioid dependence susceptibility. ( 28656735 )	Nagaya D...Yusoff NM	2018
48	Perceived stigma and social support in treatment for pharmaceutical opioid dependence. ( 28884866 )	Cooper S...Nielsen S	2018
49	Compulsivity in opioid dependence. ( 28918267 )	Tolomeo S...Baldacchino A	2018
50	Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence. ( 28930612 )	Blum K...Badgaiyan RD	2018

Sources

Genes for Opiate Dependence

Genes related to Opiate Dependence (1 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	ODS1	Opioid Dependence, Susceptibility To, 1	Genetic Locus	50	MalaCards inferred ⁴¹
2	OPRM1	Opioid Receptor Mu 1	Protein Coding	26.58	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	12960749 17416470 15558714 (more) 12648891 17503481 18193922 16536895 20357116 9756053 18424454 19403243 9517399
3	DRD3	Dopamine Receptor D3	Protein Coding	24.18	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9702743
4	OPRK1	Opioid Receptor Kappa 1	Protein Coding	23	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9365966 9517399
5	OPRD1	Opioid Receptor Delta 1	Protein Coding	22.44	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17503481 20300121
6	PDYN	Prodynorphin	Protein Coding	22.28	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9190848 16314761
7	CREB1	CAMP Responsive Element Binding Protein 1	Protein Coding	22.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	DRD2	Dopamine Receptor D2	Protein Coding	22.26	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	11054765 16583408 12497624 (more) 20305222 10881203 11256581
9	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	21.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	TH	Tyrosine Hydroxylase	Protein Coding	21.22	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	POMC	Proopiomelanocortin	Protein Coding	21.19	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	NGF	Nerve Growth Factor	Protein Coding	20.04	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	IGF1	Insulin Like Growth Factor 1	Protein Coding	16.48	GeneCards inferred via : Publications (show sections)
14	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	16.48	GeneCards inferred via : Publications (show sections)
15	TPH1	Tryptophan Hydroxylase 1	Protein Coding	16.48	GeneCards inferred via : Publications (show sections)

Sources

Variations for Opiate Dependence

Sources

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Sources

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 17)

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by GPCR ⁶⁶ Show member pathways GPCR downstream signaling ⁶⁶ Signal Transduction ⁶⁶	13.89	CREB1 DRD2 DRD3 IGF1 NGF OPRD1
2	Peptide ligand-binding receptors ⁶⁶ Show member pathways Class A/1 (Rhodopsin-like receptors) ⁶⁶ Defective AVP causes neurohypophyseal diabetes insipidus (NDI) ⁶⁶ Formyl peptide receptors bind formyl peptides and many other ligands ⁶⁶ G alpha (i) signalling events ⁶⁶ GPCR ligand binding ⁶⁶ GPCRs, Class A Rhodopsin-like ¹ Neuroactive ligand-receptor interaction ³⁷ Orexin and neuropeptides FF and QRFP bind to their respective receptors ⁶⁶ Peptide GPCRs ¹ Tachykinin receptors bind tachykinins ⁶⁶ Vasopressin-like receptors ⁶⁶	13.32	DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
3	DAG and IP3 signaling ⁶⁶ Show member pathways Beta-2 adrenergic-dependent CFTR expression ²² Ca-dependent events ⁶⁶ Calmodulin induced events ⁶⁶ CaM pathway ⁶⁶ Cam-PDE 1 activation ⁶⁶ CREB phosphorylation through the activation of Adenylate Cyclase ⁶⁶ Development Beta-adrenergic receptors signaling via cAMP ²² Development Role of Activin A in cell differentiation and proliferation ²² EGFR interacts with phospholipase C-gamma ⁶⁶ G Protein Signaling Pathways ¹ G-protein mediated events ⁶⁶ Inhibitory action of Lipoxin A4 on PDGF, EGF and LTD4 signaling ²² Neurophysiological process PGE2-induced pain processing ²² Opioid Signalling ⁶⁶ PKA activation ⁶⁶ PKA activation in glucagon signalling ⁶⁶ PKA-mediated phosphorylation of CREB ⁶⁶ PLC beta mediated events ⁶⁶ PLC-gamma1 signalling ⁶⁶ Signal transduction Calcium signaling ²²	12.85	CREB1 NGF OPRM1 PDYN POMC
4	Circadian entrainment ³⁷ Show member pathways Cholinergic synapse ³⁷ Dopaminergic synapse ³⁷ Estrogen signaling pathway ³⁷ Glutamatergic synapse ³⁷ Relaxin receptors ⁶⁶ Relaxin signaling pathway ³⁷ Synaptic Neurotransmission Pathways: Glutamatergic Excitation ⁶⁵	12.75	CREB1 DRD2 DRD3 OPRM1 TH VEGFA
5	Ras signaling pathway ³⁷ Show member pathways Rap1 signaling pathway ³⁷	12.51	DRD2 IGF1 NGF VEGFA
6	ADP signalling through P2Y purinoceptor 12 ⁶⁶ Show member pathways Adrenaline,noradrenaline inhibits insulin secretion ⁶⁶ Beta-agonist/Beta-blocker Pathway, Pharmacodynamics ⁶¹ Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding ⁶⁶ G alpha (z) signalling events ⁶⁶ G-protein activation ⁶⁶ Signal transduction cAMP signaling ²²	12.3	CREB1 OPRM1 PDYN POMC
7	Neuroscience ⁴	12.17	CREB1 NGF OPRM1 POMC TH TPH1
8	Circadian rythm related genes ¹	11.75	CREB1 DRD2 DRD3 SLC6A4 TH TPH1
9	Amphetamine addiction ³⁷ Show member pathways Cocaine addiction ³⁷	11.74	CREB1 DRD2 PDYN TH
10	Interleukin-4 and 13 signaling ⁶⁶	11.68	OPRD1 OPRM1 POMC VEGFA
11	Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics ⁶¹ Show member pathways Nicotine Activity on Dopaminergic Neurons ¹ SNARE interactions in vesicular transport ³⁷	11.66	DRD2 DRD3 TH
12	Neural Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.46	IGF1 NGF TH VEGFA
13	Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways ¹	11.31	CREB1 NGF SLC6A4 TH TPH1 VEGFA
14	Microglia Activation During Neuroinflammation: Steady-State Microglia ⁶⁵	11.26	DRD2 IGF1 NGF
15	Biogenic Amine Synthesis ¹ Show member pathways catecholamine biosynthesis ¹ Catecholamine biosynthesis ⁶⁶	10.9	TH TPH1
16	DARPP-32 Phosphorylation ⁶⁵	10.89	DRD2 DRD3
17	p38 signaling mediated by MAPKAP kinases ¹	10.83	CREB1 TH

Sources

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	integral component of plasma membrane	GO:0005887	9.93	DRD2 DRD3 OPRD1 OPRK1 OPRM1 SLC6A4
2	axon	GO:0030424	9.8	CREB1 DRD2 NGF OPRM1 TH
3	dendrite	GO:0030425	9.73	DRD2 NGF OPRK1 OPRM1 PDYN TH
4	perikaryon	GO:0043204	9.62	DRD2 OPRK1 OPRM1 TH
5	axon terminus	GO:0043679	9.46	DRD2 OPRD1 OPRK1 PDYN
6	dopaminergic synapse	GO:0098691	9.43	DRD2 DRD3
7	spine apparatus	GO:0097444	9.37	OPRD1 OPRM1
8	integral component of postsynaptic membrane	GO:0099055	9.26	DRD2 OPRK1 OPRM1 SLC6A4
9	integral component of presynaptic membrane	GO:0099056	9.02	DRD2 OPRD1 OPRK1 OPRM1 SLC6A4

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 58)

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine-mediated signaling pathway	GO:0019221	9.97	OPRD1 OPRM1 POMC VEGFA
2	negative regulation of gene expression	GO:0010629	9.95	CREB1 IGF1 OPRD1 VEGFA
3	response to drug	GO:0042493	9.92	CREB1 DRD2 DRD3 SLC6A4 TH
4	circadian rhythm	GO:0007623	9.85	CREB1 SLC6A4 TPH1
5	response to hypoxia	GO:0001666	9.83	CREB1 DRD2 SLC6A4 TH VEGFA
6	adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	GO:0007193	9.82	OPRD1 OPRK1 OPRM1
7	cellular response to growth factor stimulus	GO:0071363	9.81	CREB1 OPRD1 TH
8	phospholipase C-activating G protein-coupled receptor signaling pathway	GO:0007200	9.81	OPRD1 OPRK1 OPRM1
9	social behavior	GO:0035176	9.8	DRD3 SLC6A4 TH
10	visual learning	GO:0008542	9.78	CREB1 DRD2 DRD3
11	response to nicotine	GO:0035094	9.76	CREB1 DRD2 TH
12	memory	GO:0007613	9.76	CREB1 NGF SLC6A4 TH
13	arachidonic acid secretion	GO:0050482	9.72	DRD2 DRD3
14	response to immobilization stress	GO:0035902	9.72	TH TPH1
15	positive regulation of receptor internalization	GO:0002092	9.72	DRD2 VEGFA
16	positive regulation of neuroblast proliferation	GO:0002052	9.72	DRD2 VEGFA
17	response to amphetamine	GO:0001975	9.72	DRD2 DRD3 TH
18	response to ethanol	GO:0045471	9.72	DRD2 DRD3 OPRK1 OPRM1 TH
19	adenylate cyclase-activating adrenergic receptor signaling pathway	GO:0071880	9.71	DRD2 DRD3
20	positive regulation of Ras protein signal transduction	GO:0046579	9.71	IGF1 NGF
21	dopamine receptor signaling pathway	GO:0007212	9.71	DRD2 DRD3
22	eye photoreceptor cell development	GO:0042462	9.71	TH VEGFA
23	negative regulation of protein secretion	GO:0050709	9.71	DRD2 DRD3
24	regulation of sensory perception of pain	GO:0051930	9.71	OPRD1 OPRK1 OPRM1
25	positive regulation of long-term synaptic potentiation	GO:1900273	9.7	CREB1 DRD2
26	mammary gland alveolus development	GO:0060749	9.7	TPH1 VEGFA
27	positive regulation of CREB transcription factor activity	GO:0032793	9.7	OPRD1 VEGFA
28	estrous cycle	GO:0044849	9.7	OPRK1 OPRM1
29	response to growth factor	GO:0070848	9.69	OPRM1 TH
30	dopamine metabolic process	GO:0042417	9.69	DRD2 DRD3
31	prepulse inhibition	GO:0060134	9.69	DRD2 DRD3
32	neurotransmitter biosynthetic process	GO:0042136	9.68	SLC6A4 TH
33	positive regulation of renal sodium excretion	GO:0035815	9.68	DRD2 DRD3
34	G protein-coupled receptor internalization	GO:0002031	9.68	DRD2 DRD3
35	adenylate cyclase-activating dopamine receptor signaling pathway	GO:0007191	9.67	DRD3 OPRM1
36	behavioral response to cocaine	GO:0048148	9.67	DRD2 DRD3 OPRK1
37	response to cocaine	GO:0042220	9.67	DRD2 DRD3 OPRK1 OPRM1
38	adenylate cyclase-inhibiting dopamine receptor signaling pathway	GO:0007195	9.66	DRD2 DRD3
39	sensory perception	GO:0007600	9.66	OPRK1 OPRM1
40	aromatic amino acid family metabolic process	GO:0009072	9.65	TH TPH1
41	behavioral response to ethanol	GO:0048149	9.65	DRD2 OPRM1
42	synaptic transmission, dopaminergic	GO:0001963	9.65	DRD2 DRD3 TH
43	neuropeptide signaling pathway	GO:0007218	9.65	OPRD1 OPRK1 OPRM1 PDYN POMC
44	regulation of dopamine uptake involved in synaptic transmission	GO:0051584	9.62	DRD2 DRD3
45	negative regulation of dopamine receptor signaling pathway	GO:0060160	9.6	DRD2 DRD3
46	acid secretion	GO:0046717	9.58	DRD2 DRD3
47	opioid receptor signaling pathway	GO:0038003	9.58	OPRD1 OPRK1 OPRM1
48	regulation of locomotion involved in locomotory behavior	GO:0090325	9.57	DRD2 DRD3
49	response to histamine	GO:0034776	9.56	DRD2 DRD3
50	adenylate cyclase-inhibiting opioid receptor signaling pathway	GO:0031635	9.51	OPRK1 OPRM1

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	G protein-coupled receptor activity	GO:0004930	9.85	DRD2 DRD3 OPRD1 OPRK1 OPRM1
2	adrenergic receptor activity	GO:0004935	9.43	DRD2 DRD3
3	dopamine neurotransmitter receptor activity, coupled via Gi/Go	GO:0001591	9.4	DRD2 DRD3
4	receptor serine/threonine kinase binding	GO:0033612	9.37	OPRD1 OPRK1
5	neuropeptide binding	GO:0042923	9.33	OPRD1 OPRK1 OPRM1
6	dopamine neurotransmitter receptor activity	GO:0004952	9.32	DRD2 DRD3
7	oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen	GO:0016714	9.26	TH TPH1
8	dopamine binding	GO:0035240	9.13	DRD2 DRD3 TH
9	opioid receptor activity	GO:0004985	8.8	OPRD1 OPRK1 OPRM1

Sources

Sources for Opiate Dependence

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Opiate Dependence

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Classifications:

External Ids:

Summaries for Opiate Dependence

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Opiate Dependence:

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

Publications for Opiate Dependence

Articles related to Opiate Dependence:

Genes for Opiate Dependence

Genes related to Opiate Dependence (1 elite genes):

Variations for Opiate Dependence

Expression for Opiate Dependence

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

Sources for Opiate Dependence

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :